异动解读｜科伦博泰生物盘中上涨7.58%，ASCO年会肺癌III期临床达主要终点叠加多项口头报告入选

行情直击05-22

5月22日，科伦博泰生物盘中上涨7.58%，报479.8港元，成交额1.47亿港元。

消息面上，公司当日公告将在ASCO年会上公布多项临床研究成果，核心产品TROP2 ADC芦康沙妥珠单抗（sac-TMT）及RET抑制剂富马酸仑博替尼两项注册研究入选转移性非小细胞肺癌口头报告专场。数据显示，sac-TMT联合帕博利珠单抗一线治疗PD-L1阳性晚期非小细胞肺癌的III期临床已达主要终点，较单药显著延长无进展生存期，客观缓解率提升至70.2%，安全性总体可控。此外，公司与默沙东合作的sac-TMT在子宫内膜癌III期TroFuse-005研究中此前已成功达到OS与PFS双主要终点，多项全球III期临床接连告捷持续催化市场情绪。

（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1191401929?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-22 09:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191401929","market":"hk","top_or_hot":-1,"title":"异动解读｜科伦博泰生物盘中上涨7.58%，ASCO年会肺癌III期临床达主要终点叠加多项口头报告入选","media":"行情直击","content":"<p><p>5月22日，科伦博泰生物盘中上涨7.58%，报479.8港元，成交额1.47亿港元。</p><p>消息面上，公司当日公告将在ASCO年会上公布多项临床研究成果，核心产品TROP2 ADC芦康沙妥珠单抗（sac-TMT）及RET抑制剂富马酸仑博替尼两项注册研究入选转移性非小细胞肺癌口头报告专场。数据显示，sac-TMT联合帕博利珠单抗一线治疗PD-L1阳性晚期非小细胞肺癌的III期临床已达主要终点，较单药显著延长无进展生存期，客观缓解率提升至70.2%，安全性总体可控。此外，公司与默沙东合作的sac-TMT在子宫内膜癌III期TroFuse-005研究中此前已成功达到OS与PFS双主要终点，多项全球III期临床接连告捷持续催化市场情绪。</p><p>（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读｜科伦博泰生物盘中上涨7.58%，ASCO年会肺癌III期临床达主要终点叠加多项口头报告入选</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读｜科伦博泰生物盘中上涨7.58%，ASCO年会肺癌III期临床达主要终点叠加多项口头报告入选\n</h2>\n\n<h4 class=\"meta\">\n\n2026-05-22 09:36 北京时间&nbsp;&nbsp;&nbsp;<strong>行情直击</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月22日，科伦博泰生物盘中上涨7.58%，报479.8港元，成交额1.47亿港元。消息面上，公司当日公告将在ASCO年会上公布多项临床研究成果，核心产品TROP2 ADC芦康沙妥珠单抗（sac-TMT）及RET抑制剂富马酸仑博替尼两项注册研究入选转移性非小细胞肺癌口头报告专场。数据显示，sac-TMT联合帕博利珠单抗一线治疗PD-L1阳性晚期非小细胞肺癌的III期临床已达主要终点，较单药显著延长...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物","start_time":0,"source_url":"","article_id":"1191401929","we_media_id":"1059448697","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191401929","pubTimestamp":1779413789,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"行情直击","introduction":"个股异动一手消息解读","home_visible":1,"id":"1059448697","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"5月22日，科伦博泰生物盘中上涨7.58%，报479.8港元，成交额1.47亿港元。消息面上，公司当日公告将在ASCO年会上公布多项临床研究成果，核心产品TROP2 ADC芦康沙妥珠单抗及RET抑制剂富马酸仑博替尼两项注册研究入选转移性非小细胞肺癌口头报告专场。数据显示，sac-TMT联合帕博利珠单抗一线治疗PD-L1阳性晚期非小细胞肺癌的III期临床已达主要终点，较单药显著延长无进展生存期，客观缓解率提升至70.2%，安全性总体可控。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"06990":"科伦博泰生物"},"translate_title":"Interpretation of the change | Kelunbotai Biotech rose by 7.58% in the intraday session, and the ASCO annual meeting lung cancer phase III clinical trial reached the primary endpoint and multiple oral reports were selected","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":1},"content_text":"5月22日，科伦博泰生物盘中上涨7.58%，报479.8港元，成交额1.47亿港元。消息面上，公司当日公告将在ASCO年会上公布多项临床研究成果，核心产品TROP2 ADC芦康沙妥珠单抗（sac-TMT）及RET抑制剂富马酸仑博替尼两项注册研究入选转移性非小细胞肺癌口头报告专场。数据显示，sac-TMT联合帕博利珠单抗一线治疗PD-L1阳性晚期非小细胞肺癌的III期临床已达主要终点，较单药显著延长无进展生存期，客观缓解率提升至70.2%，安全性总体可控。此外，公司与默沙东合作的sac-TMT在子宫内膜癌III期TroFuse-005研究中此前已成功达到OS与PFS双主要终点，多项全球III期临床接连告捷持续催化市场情绪。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1191401929","isCrawlerRequest":true}